Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1
Cosimo Walter D’Acunto, Bianca Fontanella, Manuela Rodriquez, Maurizio Taddei, Luca Parente, Antonello Petrella
20100801
2010 Sept 1
Cancer Lett
Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1
Cancer Lett. 2010 Sept 01;295(1):85-91, Cosimo Walter D’Acunto, Bianca Fontanella, Manuela Rodriquez, Maurizio Taddei, Luca Parente, Antonello Petrella
The reduction of Annexin A1 (ANXA1) expression, commonly associated with prostate cancer, could be due to elevated activity of histone deacetylases. We have investigated the mechanisms of apoptotic effects of FR235222 in LNCaP cell line and the role of ANXA1. We showed that treatment with FR235222 induced apoptosis through a caspase-dependent mechanism. FR235222 was able to increase the protein levels of ANXA1 at a transcriptional level. Finally, the inhibition of ANXA1 expression by siRNA leads...
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
